Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implicationsSutapa Sinha(Mayo Clinic), Neil E. Kay(Mayo Clinic)British Journal of CancerJune 17, 202410.1038/s41416-024-02752-1Cited by 0SaveCiteExport RISWatch citationsRelated PapersCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia|Blood|2006|293Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells|Blood|2009|140